June 2023 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 -
Recent Posts
Topics
- AI (2)
- Creativity (5)
- Crowdsourcing (71)
- Diversity (7)
- Global Innovation (29)
- Health Care (13)
- Innovation (121)
- Innovation Service Providers (5)
- Internal Innovation Networks (9)
- Internet (3)
- Open Innovation (3)
- Portfolio Management (9)
- Rewards and Recognition (9)
- Startups (13)
- Uncategorized (2)
Archives
- December 2022
- November 2022
- July 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- October 2020
- September 2020
- August 2020
- July 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- April 2019
- March 2019
- January 2019
- November 2018
- July 2018
- June 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- January 2015
- December 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
Social
-
- Follow on WordPress.com
Tag Archives: FDA
A boomerang drug
On June 7, the U.S. Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s Disease (AD), its first in nearly two decades. Manufactured by Biogen (a biotech company based in Cambridge, MA) and called Aduhelm, the drug was … Continue reading
Posted in Global Innovation, Health Care
Tagged Aduhelm, AIDS, Alzheimer’s Association, Alzheimer’s disease, Biogen, consumer-centric healthcare, FDA
Leave a comment
All Innovation Is Local
I like this phrase: all politics is local. Ascribed to the late Speaker of the U.S. House of Representatives Tip O’Neill this phrase means that all political decisions, regardless of their purpose and scale, must take into account the interests … Continue reading
Posted in Health Care
Tagged Clinical Trials, consumer-centric healthcare, Crowdsourcing, disease advocacy organizations, Drug Development, druggable molecular targets, FDA, Innovation, Innovation Management, Open Innovation, patient groups, Phase III clinical trials, R&D processes, rapid prototyping, Tip O’Neill, Transparency Life Sciences, unmet customer needs, unmet medical needs, VOC, voice of the customer
Leave a comment
Should We Celebrate Failure Worth A Billion?
As every popular topic, innovation is a powerful magnet for clichés. Some of them obliterate more than illuminate. For example, I’m not sure that mixing innovation with DNA is a good idea. Though I kind of understand what Clayton Christensen … Continue reading
Posted in Portfolio Management
Tagged cancer, Clayton Christensen, Clinical Trials, Drug Development, FDA, Innovation, Phase III, The innovator’s DNA
11 Comments
The Outsider Effect
Better decisions come from teams that include a “socially distinct newcomer”…someone who is different enough to bump other team member out of their comfort zones (From Kellog School of Management News, Embracing the “socially distinct outsider”) There are many things … Continue reading
innovationobserver.com 